Author:
Mansell James,Monypenny Ian J.,Skene Anthony I.,Abram Paul,Carpenter Robert,Gattuso Jennifer M.,Wilson Christopher R.,Angerson Wilson J.,Doughty Julie C.
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. doi: 10.1016/S0140-6736(05)66544-0
2. Howell A, ATAC Trialists’ Group (2004) ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) completed treatment analysis: anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen [abstract 1]. Presented at the 27th Annual San Antonio breast cancer symposium; San Antonio, TX, 8–11 December
3. Howell A, Cuzick J, Baum M, ATAC Trialists’ Group et al (2005) Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62. doi: 10.1016/S0140-6736(05)74803-0
4. Thürlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757. doi: 10.1056/NEJMoa052258
5. Coombes RC, Kilburn LS, Snowdon CF, Intergroup Exemestane Study et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570. doi: 10.1016/S0140-6736(07)60200-1 (Erratum in: Lancet 2007;369:906)
Cited by
63 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献